Bifogade filer
Modus Therapeutics data to be presented at the 32nd Symposium on Glycosaminoglycans – sevuparin in focus for CKD with anemia
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, Sweden – 18 September 2025 — Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical need, announces that the Company’s collaborator, Professor Maura Poli (University of Brescia), has been invited to present our joint research on anemia and chronic kidney disease (CKD) at the 32nd Symposium on Glycosaminoglycans, held 18–20 September 2025 at Villa Vigoni, Loveno di Menaggio, Italy. The symposium is an invitation-only summit for world-leading experts in glycosaminoglycans (GAGs) and their clinical applications.
The presentation builds on new preclinical data showcased by Modus and the Brescia team at EHA 2025 (Milan, 14 June 2025). In a well-established CKD model, sevuparin improved both anemia and kidney status, with reduced expression of fibrosis and injury markers; and the effects were observed both at monotherapy and in combination with erythropoietin (EPO). The results align with sevuparin’s hepcidin-lowering activity and strengthen the rationale for treating CKD with anemia.
Modus is delivering according to plan in its clinical program: Part 1 of the ongoing Phase 2a study in patients with CKD and anemia has been completed. Part 2 of the study, aiming for proof-of-concept, is being prepared to start in Q4 2025. The scientific advances during the year — including new data at BioIron and EHA 2025 — have further strengthened sevuparin’s differentiated mechanism.
Quote, CEO John Öhd:
“With the development of sevuparin, Modus is a pioneer in developing medicines from the unique carbohydrate (sugar)-based group of biomolecules known as glycosaminoglycans (GAGs). Our long-standing research together with leading academic groups shows that sevuparin can modulate key factors that drive inflammation- and iron/hepcidin-dysregulated anemia. Receiving attention at an international GAG summit underscores the molecule’s distinctive profile and clinical potential — and it comes as we move into the next step of our Phase 2 program.”
About the presentation at the GAG Symposium
• Speaker: Prof. Maura Poli (University of Brescia)
• Session: Heparinoids: Challenges and Advances
• Title: Heparin and Heparan Sulfate in Iron Metabolism
• Time: Saturday, 20 September 2025, 11:20–11:40 (Villa Vigoni)